{"protocolSection": {"identificationModule": {"nctId": "NCT00631917", "orgStudyIdInfo": {"id": "CSPP100A2404"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension", "officialTitle": "A 54 Week, Randomized, Double-blind, Parallel-group, Multicenter Study Evaluating the Long-term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-02"}, "primaryCompletionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-03", "studyFirstSubmitQcDate": "2008-03-07", "studyFirstPostDateStruct": {"date": "2008-03-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-05", "resultsFirstSubmitQcDate": "2011-05-18", "resultsFirstPostDateStruct": {"date": "2011-06-21", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-06-30", "lastUpdatePostDateStruct": {"date": "2011-07-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Study Director", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients \u2265 50 years with essential hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, aliskiren, ramipril, colonoscopy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 774, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren", "type": "EXPERIMENTAL", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.", "interventionNames": ["Drug: Aliskiren", "Other: Placebo to Ramipril"]}, {"label": "Ramipril", "type": "ACTIVE_COMPARATOR", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.", "interventionNames": ["Drug: Ramipril", "Other: Placebo to Aliskiren"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren 300 mg once a day", "armGroupLabels": ["Aliskiren"]}, {"type": "DRUG", "name": "Ramipril", "description": "Ramipril 10 mg once a day", "armGroupLabels": ["Ramipril"]}, {"type": "OTHER", "name": "Placebo to Ramipril", "description": "Placebo capsules to match ramipril.", "armGroupLabels": ["Aliskiren"]}, {"type": "OTHER", "name": "Placebo to Aliskiren", "description": "Placebo tablets to match aliskiren.", "armGroupLabels": ["Ramipril"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants With Colonic Pathology", "description": "The primary analysis variable was the occurrence of an abnormal colonoscopy finding (defined as hyper-plastic polyps, inflammatory polyps, adenomatous polyps or carcinoma) at or prior to the planned one year visit. The occurrence of colonic pathology was identified during colonoscopy and histopathologic examination of biopsy. The composite endpoint was evaluated after one year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.", "timeFrame": "54 weeks"}, {"measure": "Summary of the End of Study Colonoscopy Results", "description": "During each colonoscopy procedure, random biopsy samples were taken from normal appearing mucosa in both the cecum and rectum in addition to obvious endoscopically atypical areas. The mucosal biopsy samples were evaluated for mucosal hyperplasia, dysplasia, and inflammation. Anything noted as a distinct visual abnormality from cecum to rectum such as ulcers, erythematous mucosa, or polyps, was photographed and biopsied for histopathology evaluation. Colonic lesions were categorized according to location in the colon, size, number, and morphology.", "timeFrame": "54 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Participants With Each of the Individual Components of Colonic Pathology", "description": "Assessment of the occurrence of the individual components (hyperplastic polyps, inflammatory polyps, adenomatous polyps or carcinomas) of the composite endpoint (colonic pathology) following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.", "timeFrame": "54 weeks"}, {"measure": "Mucosal Hyperplasia Score in Rectal and Cecal Mucosal Biopsy Specimens After One Year of Treatment", "description": "Maximum hyperplasia score at end of study across rectal and cecal mucosa biopsy specimens. Score of 0 is no change from baseline, the minimum possible score. Score \\> 0 is worsening from baseline in which the maximum possible score is 3.", "timeFrame": "54 weeks"}, {"measure": "Percentage of Participants Achieving the Mean Sitting Blood Pressure Control Target", "description": "The mean sitting blood pressure control target is defined as less than 140/90 mmHg (or 130/80 mmHg for diabetic patients)", "timeFrame": "Weeks 8, 30 and End of Study (54 weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients, 50 years of age and older with a diagnosis of essential hypertension\n* Successful high quality colonoscopy at baseline including visualization of the entire colon and the cecum as confirmed by a photograph and collection of the rectal and cecal mucosal biopsy samples\n* All rectal, colon or cecal polyps found at baseline colonoscopy must be completely resected endoscopically at the time of the procedure.\n* Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation have been clearly explained to them (written informed consent).\n\nExclusion Criteria:\n\n* Previously treated in an aliskiren study.\n* Current evidence of inflammatory bowel disease, the presence of colonic ulcerations (or other indices of colitis of any type) or colorectal carcinoma including carcinoma in situ found at baseline colonoscopy.\n* History of gastrointestinal carcinoma, Crohn's disease, ulcerative colitis, microscopic colitis.\n* History of familial polyposis or hereditary nonpolyposis colorectal cancer.\n* History of confirmed diverticulitis within 12 months of Visit 1.\n* History of celiac disease (gluten intolerance).\n* History of or current evidence on the baseline colonoscopy of melanosis coli.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "50 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "862-778-8300", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Investigative Site", "city": "Kansas City", "state": "Missouri", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Investigative Site", "city": "Investigative Site", "country": "Argentina"}, {"facility": "Investigative Site", "city": "Investigative Site", "country": "Colombia"}, {"facility": "Investigative Site", "city": "Investigative Site", "country": "France"}, {"facility": "Investigative Site", "city": "Investigative Site", "country": "Germany"}, {"facility": "Investigative Site", "city": "investigative Site", "country": "India"}, {"facility": "Investigative Site", "city": "Investigative Site", "country": "Spain"}]}, "referencesModule": {"references": [{"pmid": "33089502", "type": "DERIVED", "citation": "Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "FG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "375"}, {"groupId": "FG001", "numSubjects": "399"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "287"}, {"groupId": "FG001", "numSubjects": "291"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "88"}, {"groupId": "FG001", "numSubjects": "108"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "No longer required study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "25"}, {"groupId": "FG001", "numSubjects": "33"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "BG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "375"}, {"groupId": "BG001", "value": "399"}, {"groupId": "BG002", "value": "774"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.3", "spread": "6.99"}, {"groupId": "BG001", "value": "59.3", "spread": "6.65"}, {"groupId": "BG002", "value": "59.3", "spread": "6.81"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "299"}, {"groupId": "BG001", "value": "313"}, {"groupId": "BG002", "value": "612"}]}]}, {"title": "65 years and greater", "categories": [{"measurements": [{"groupId": "BG000", "value": "76"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "162"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "194"}, {"groupId": "BG001", "value": "194"}, {"groupId": "BG002", "value": "388"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "181"}, {"groupId": "BG001", "value": "205"}, {"groupId": "BG002", "value": "386"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants With Colonic Pathology", "description": "The primary analysis variable was the occurrence of an abnormal colonoscopy finding (defined as hyper-plastic polyps, inflammatory polyps, adenomatous polyps or carcinoma) at or prior to the planned one year visit. The occurrence of colonic pathology was identified during colonoscopy and histopathologic examination of biopsy. The composite endpoint was evaluated after one year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.", "populationDescription": "Primary Analysis Set, consisting of all randomized patients that had post-baseline colonoscopy procedure performed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "OG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "325"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.5"}, {"groupId": "OG001", "value": "25.1"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Each of the Individual Components of Colonic Pathology", "description": "Assessment of the occurrence of the individual components (hyperplastic polyps, inflammatory polyps, adenomatous polyps or carcinomas) of the composite endpoint (colonic pathology) following one-year of treatment with an aliskiren-based regimen compared to a ramipril-based regimen.", "populationDescription": "Primary analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "OG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "325"}]}], "classes": [{"title": "Hyperplastic polyps", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.1"}, {"groupId": "OG001", "value": "10.2"}]}]}, {"title": "Inflammatory polyps", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.3"}]}]}, {"title": "Adenomatous polyps", "categories": [{"measurements": [{"groupId": "OG000", "value": "15.0"}, {"groupId": "OG001", "value": "17.3"}]}]}, {"title": "Carcinoma", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Mucosal Hyperplasia Score in Rectal and Cecal Mucosal Biopsy Specimens After One Year of Treatment", "description": "Maximum hyperplasia score at end of study across rectal and cecal mucosa biopsy specimens. Score of 0 is no change from baseline, the minimum possible score. Score \\> 0 is worsening from baseline in which the maximum possible score is 3.", "populationDescription": "Primary analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "OG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "325"}]}], "classes": [{"title": "Score = 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "304"}]}]}, {"title": "Score = 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Score = 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Score = 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Score is Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving the Mean Sitting Blood Pressure Control Target", "description": "The mean sitting blood pressure control target is defined as less than 140/90 mmHg (or 130/80 mmHg for diabetic patients)", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Weeks 8, 30 and End of Study (54 weeks)", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "OG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "374"}, {"groupId": "OG001", "value": "394"}]}], "classes": [{"title": "Week 8", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.8"}, {"groupId": "OG001", "value": "44.9"}]}]}, {"title": "Week 30", "categories": [{"measurements": [{"groupId": "OG000", "value": "60.2"}, {"groupId": "OG001", "value": "54.1"}]}]}, {"title": "End of Study", "categories": [{"measurements": [{"groupId": "OG000", "value": "65.0"}, {"groupId": "OG001", "value": "56.1"}]}]}]}, {"type": "PRIMARY", "title": "Summary of the End of Study Colonoscopy Results", "description": "During each colonoscopy procedure, random biopsy samples were taken from normal appearing mucosa in both the cecum and rectum in addition to obvious endoscopically atypical areas. The mucosal biopsy samples were evaluated for mucosal hyperplasia, dysplasia, and inflammation. Anything noted as a distinct visual abnormality from cecum to rectum such as ulcers, erythematous mucosa, or polyps, was photographed and biopsied for histopathology evaluation. Colonic lesions were categorized according to location in the colon, size, number, and morphology.", "populationDescription": "Primary Analysis Set, consisting of all randomized patients that had post-baseline colonoscopy procedure performed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "54 weeks", "groups": [{"id": "OG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration."}, {"id": "OG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "325"}]}], "classes": [{"title": "Complete colonoscopy performed", "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Was cecum reached in procedure", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.7"}, {"groupId": "OG001", "value": "100"}]}]}, {"title": "Photos obtained", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.4"}, {"groupId": "OG001", "value": "99.7"}]}]}, {"title": "Took drug affecting bowel function", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.6"}]}]}, {"title": "Took low dose aspirin during wk prior to procedure", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8"}, {"groupId": "OG001", "value": "5.2"}]}]}, {"title": "Adequacy of bowel preparation - Optimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.3"}, {"groupId": "OG001", "value": "73.5"}]}]}, {"title": "Adequacy of bowel preparation - Suboptimal", "categories": [{"measurements": [{"groupId": "OG000", "value": "27.4"}, {"groupId": "OG001", "value": "25.5"}]}]}, {"title": "Adequacy of bowel preparation - Inadequate", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3"}, {"groupId": "OG001", "value": "0.9"}]}]}, {"title": "Colonoscopy prep given- PEG containing solution", "categories": [{"measurements": [{"groupId": "OG000", "value": "96.8"}, {"groupId": "OG001", "value": "97.2"}]}]}, {"title": "Colonoscopy prep given - Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2"}, {"groupId": "OG001", "value": "2.8"}]}]}, {"title": "Occurrence of colon polyps", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.6"}, {"groupId": "OG001", "value": "26.5"}]}]}, {"title": "Patients with polyps-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8"}, {"groupId": "OG001", "value": "11.4"}]}]}, {"title": "Patients with polyps-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.1"}, {"groupId": "OG001", "value": "5.2"}]}]}, {"title": "Patients with polyps-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.1"}, {"groupId": "OG001", "value": "11.7"}]}]}, {"title": "Patients with polyps-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "8.0"}, {"groupId": "OG001", "value": "6.5"}]}]}, {"title": "Mean number of polyps-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "1.2"}]}]}, {"title": "Mean number of polyps-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2"}, {"groupId": "OG001", "value": "1.4"}]}]}, {"title": "Mean number of polyps-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.5"}, {"groupId": "OG001", "value": "1.5"}]}]}, {"title": "Mean number of polyps-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.6"}, {"groupId": "OG001", "value": "1.3"}]}]}, {"title": "Polyps were completely resected-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8"}, {"groupId": "OG001", "value": "11.1"}]}]}, {"title": "Polyps were completely resected-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.1"}, {"groupId": "OG001", "value": "4.9"}]}]}, {"title": "Polyps were completely resected-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "12.1"}, {"groupId": "OG001", "value": "11.7"}]}]}, {"title": "Polyps were completely resected-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.6"}, {"groupId": "OG001", "value": "6.5"}]}]}, {"title": "Photo taken for polyps-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.8"}, {"groupId": "OG001", "value": "11.1"}]}]}, {"title": "Photo taken for polyps-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7"}, {"groupId": "OG001", "value": "4.6"}]}]}, {"title": "Photo taken for polyps-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "10.8"}, {"groupId": "OG001", "value": "10.5"}]}]}, {"title": "Photo taken for polyps-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.6"}, {"groupId": "OG001", "value": "6.2"}]}]}, {"title": "Mucosal abnormalities for colitis", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.3"}, {"groupId": "OG001", "value": "1.5"}]}]}, {"title": "Patients with colitis-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.9"}]}]}, {"title": "Patients with colitis-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Patients with colitis-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Patients with colitis-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.6"}]}]}, {"title": "Area of colitis biopsied-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.9"}]}]}, {"title": "Area of colitis biopsied-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Area of colitis biopsied-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Area of colitis biopsied-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.6"}]}]}, {"title": "Area of colitis photographed-Cecum/ascending", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.9"}]}]}, {"title": "Area of colitis photographed-Transverse", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Area of colitis photographed-Descending/sigmoid", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Area of colitis photographed-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.6"}]}]}, {"title": "Normal mucosal biopsies collected-Cecum", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.4"}, {"groupId": "OG001", "value": "99.7"}]}]}, {"title": "Normal mucosal biopsies collected-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.7"}, {"groupId": "OG001", "value": "99.7"}]}]}, {"title": "Mean number of normal mucosal biopsies-Cecum", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0"}, {"groupId": "OG001", "value": "3.0"}]}]}, {"title": "Mean number of normal mucosal biopsies-Rectum", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0"}, {"groupId": "OG001", "value": "3.0"}]}]}, {"title": "Malignance for any biopsy samples-Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Malignance for any biopsy samples-No", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.4"}, {"groupId": "OG001", "value": "98.8"}]}]}, {"title": "Malignance for any biopsy samples-Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.9"}]}]}, {"title": "Inflammation for any biopsy samples-Yes", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0"}, {"groupId": "OG001", "value": "0.6"}]}]}, {"title": "Inflammation for any biopsy samples-No", "categories": [{"measurements": [{"groupId": "OG000", "value": "98.4"}, {"groupId": "OG001", "value": "98.8"}]}]}, {"title": "Inflammation for any biopsy samples-Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6"}, {"groupId": "OG001", "value": "0.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren", "description": "For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.", "seriousNumAffected": 28, "seriousNumAtRisk": 375, "otherNumAffected": 163, "otherNumAtRisk": 375}, {"id": "EG001", "title": "Ramipril", "description": "For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.", "seriousNumAffected": 22, "seriousNumAtRisk": 399, "otherNumAffected": 176, "otherNumAtRisk": 399}], "seriousEvents": [{"term": "Atrioventricular block complete", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Hyperparathyroidism primary", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Diarrhoea haemorrhagic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Lower gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Type III immune complex mediated reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "In-stent arterial restenosis", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Meniscus lesion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Facial palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Occipital neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 399}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Cystitis haemorrhagic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Laryngeal oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Aortic dissection", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Arteritis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 399}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}, {"term": "Hypertensive emergency", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 399}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 399}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 399}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 399}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 399}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 399}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 399}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 399}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 399}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 54, "numAtRisk": 399}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 375}, {"groupId": "EG001", "numAffected": 48, "numAtRisk": 399}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Peru"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017257", "term": "Ramipril"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}